XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems [Canadian Business Journal (Canada)]
XORTX Therapeutics Inc. (XRTX)
Company Research
Source: Canadian Business Journal
CALGARY, Alberta, Oct. 17, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“Companynovel new chemical entity, VB4-P5pre-IND (Investigational New Drug)Dr. Allen Davidoff, Chief Executive Officer of XORTX, stated, “The opportunity to acquire the VB4-P5 program was highly compelling. This program is underpinned by a novel, patented small molecule with robust global patent protection and strong preclinical evidence. It is directly aligned with our strategic focus on developing innovative therapies for progressive kidney disease, and it builds upon our mission to bring new classes of treatments to patients suffering from rare renal disorders.”The Term Sheet provides for XORTX to acquire from Vectus the intellectual property specifically related to the VB4-P5 compound and the data generated by Vectus from its work on the VB4-P5 small molecule and related assets. The consideration receivable by Vectus is USD $3.0 million, payable in common shares or common share equivalents of XORTX (the “S
Show less
Read more
Impact Snapshot
Event Time:
XRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XRTX alerts
High impacting XORTX Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
XRTX
News
- XORTX Announces Closing of US$1.1 Million Registered Direct Offering [Canadian Business Journal (Canada)]Canadian Business Journal
- XORTX Announces Closing of US$1.1 Million Registered Direct OfferingGlobeNewswire
- XORTX Announces Pricing of US$1.1 Million Registered Direct Offering [Canadian Business Journal (Canada)]Canadian Business Journal
- XORTX Announces Pricing of US$1.1 Million Registered Direct OfferingGlobeNewswire
- XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price DeficiencyGlobeNewswire
XRTX
Sec Filings
- 11/17/25 - Form 6-K
- 10/31/25 - Form 6-K
- 10/29/25 - Form 6-K
- XRTX's page on the SEC website